News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Subscribe

Spotlight -

Predictions for 2026: Our January 2026 issue|

MHE State of the Industry survey|

AMCP Nexus 2025|

2025 Fall Clinical Dermatology|

Opinion|Videos|August 16, 2024

Overall Experience With Intravenous Biologics

Author(s)Jennifer Seminerio, MD

Dr. Jennifer Seminerio discusses what what her overall perspective with intravenous biologics in gastrointestinal diseases

Episodes in this series

EP. 1 Indication and Practical Utilization of IV and Subcutaneous Biologics

EP. 1 Indication and Practical Utilization of IV and Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 2 Key Consideration and Concerns Around IV and Subcutaneous Biologic Use

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 3 Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 4 Key Patient Factors in Determining an Optimal Biologic Therapy

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 5 Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 6 Future Predictions for Intravenous and Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 7 Overall Experience With Intravenous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 8 Clinical Insights With Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 9 Innovations Associated With IV Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 10 Exciting Developments With Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 11 Positioning Intravenous and Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 12 Adherence With Intravenous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 13 Billing With Intravenous and Subcutaneous Therapies

Jennifer Seminerio, MD, a gastroenterologist

EP. 14 Evaluating Efficacy Between Intravenous and Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 15 Cost Considerations With Intravenous and Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 16 Patient Experience With Intravenous and Subcutaneous Therapies

Jennifer Seminerio, MD, a gastroenterologist

EP. 17 Role of Biosimilars in Gastrointestinal Diseases

Jennifer Seminerio, MD, a gastroenterologist

EP. 18 Future Direction of Intravenous and Subcutaneous Biologics

EP. 19 K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies

EP. 19 K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies

Video content above is prompted by the following questions:

How long have you been using IV biologics in your practice, for which indications, and what has your overall experience been like?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Related Content

Kyverna to submit BLA for investigational CAR-T therapy for stiff-person syndrome

December 18th 2025

Investigational treatment for primary immune thrombocytopenia shows promise in trial

December 10th 2025

Hydrotherapy more beneficial for MS patients than conventional physiotherapy

December 5th 2025

Stanford scientists find link between Epstein-Barr virus and lupus

December 2nd 2025

Global MS analysis links disability burden to rising economic strain

November 29th 2025

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Huntington Beach Symposia

In-Person + Virtual Event

Huntington Beach Symposia

February 19-21, 2026

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO

The 4th Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

The 4th Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Nicolas Villanueva, MD

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Manmeet Ahluwalia, MD, MBA

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Zofia Piotrowska, MD, MHS; Bruna Pellini, MD; Alice Shaw, MD, PhD

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Marina Chiara Garassino, MD; Sarah Goldberg, MD, MPH; Biagio Ricciuti, MD, PhD

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Jacob Sands, MD; Anne Chiang, MD, PhD; Alissa J. Cooper, MD

22nd Annual Winter Lung Cancer Conference®

22nd Annual Winter Lung Cancer Conference®

Julie Brahmer, MD; Rogerio C. Lilenbaum, MD, FACP, FASCO; Mark A. Socinski, MD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Trending on Managed Healthcare Executive

7 things you need to know about the PBM reforms signed into law this week

PBM reform. It has finally happened

TrumpRx launches; some experts question its long-term value

FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals

Cancer survival fell and deaths rose during first two years of COVID-19